Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
13.56
+0.22 (1.65%)
Jan 21, 2025, 4:00 PM EST - Market closed
Bicycle Therapeutics Employees
Bicycle Therapeutics had 284 employees as of December 31, 2023. The number of employees increased by 48 or 20.34% compared to the previous year.
Employees
284
Change (1Y)
48
Growth (1Y)
20.34%
Revenue / Employee
$129,923
Profits / Employee
-$585,479
Market Cap
936.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
BCYC News
- 8 days ago - Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones - Business Wire
- 12 days ago - Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 18 days ago - Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification - Business Wire
- 6 weeks ago - Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts - Business Wire
- 2 months ago - Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update - Business Wire
- 2 months ago - Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference - Business Wire
- 2 months ago - Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern - Seeking Alpha